标签归档：cancerous

PP2A Cancerous-IN-1

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

PP2A Cancerous-IN-1 

PP2A Cancerous-IN-1 是一种强效的 CIP2A (Cancerous inhibitor of PP2A)和 p-Akt 抑制剂。PP2A Cancerous-IN-1显示出很强的抗增殖活性。

PP2A Cancerous-IN-1

PP2A Cancerous-IN-1 Chemical Structure

CAS No. : 1403933-79-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PP2A Cancerous-IN-1 is a strong and potent CIP2A (Cancerous inhibitor of PP2A) and p-Akt inhibitor. PP2A Cancerous-IN-1 shows the most potent antiproliferative activities[1].

IC50 & Target[1]

pAKT

 

体外研究
(In Vitro)

PP2A Cancerous-IN-1 (2.5 and 5 μM; 24 hours; SK-Hep-1 cells) reduces CIP2A expression and cell viability with a dose dependent manner and is more potent in its action than erlotinib[1].
PP2A Cancerous-IN-1 (5 μM; 24 hours; SK-Hep-1 cells) induces cell apoptosis[1].
PP2A Cancerous-IN-1 shows CIP2A inhibitory activity, reduces p-Akt level, induces PARP cleavage. PP2A Cancerous-IN-1 exhibits high potency with low IC50 values of 2.8 μM against HCC cells[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: SK-Hep-1 cells
Concentration: 2.5 and 5 μM
Incubation Time: 24 hours
Result: Reduced cell viability with a dose dependent manner.

Western Blot Analysis[1]

Cell Line: SK-Hep-1 cells
Concentration: 2.5 and 5 μM
Incubation Time: 24 hours
Result: Reduced CIP2A expression.

Apoptosis Analysis[1]

Cell Line: SK-Hep-1 cells
Concentration: 2.5 and 5 μM
Incubation Time: 24 hours
Result: Induced cell apoptosis.

分子量

488.54

Formula

C30H24N4O3
CAS 号

1403933-79-8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Chen KF, et al. Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity. Bioorg Med Chem. 2012;20(20):6144-6153.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

PP2A Cancerous-IN-1

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

PP2A Cancerous-IN-1 

PP2A Cancerous-IN-1 是一种强效的 CIP2A (Cancerous inhibitor of PP2A)和 p-Akt 抑制剂。PP2A Cancerous-IN-1显示出很强的抗增殖活性。

PP2A Cancerous-IN-1

PP2A Cancerous-IN-1 Chemical Structure

CAS No. : 1403933-79-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PP2A Cancerous-IN-1 is a strong and potent CIP2A (Cancerous inhibitor of PP2A) and p-Akt inhibitor. PP2A Cancerous-IN-1 shows the most potent antiproliferative activities[1].

IC50 & Target[1]

pAKT

 

体外研究
(In Vitro)

PP2A Cancerous-IN-1 (2.5 and 5 μM; 24 hours; SK-Hep-1 cells) reduces CIP2A expression and cell viability with a dose dependent manner and is more potent in its action than erlotinib[1].
PP2A Cancerous-IN-1 (5 μM; 24 hours; SK-Hep-1 cells) induces cell apoptosis[1].
PP2A Cancerous-IN-1 shows CIP2A inhibitory activity, reduces p-Akt level, induces PARP cleavage. PP2A Cancerous-IN-1 exhibits high potency with low IC50 values of 2.8 μM against HCC cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: SK-Hep-1 cells
Concentration: 2.5 and 5 μM
Incubation Time: 24 hours
Result: Reduced cell viability with a dose dependent manner.

Western Blot Analysis[1]

Cell Line: SK-Hep-1 cells
Concentration: 2.5 and 5 μM
Incubation Time: 24 hours
Result: Reduced CIP2A expression.

Apoptosis Analysis[1]

Cell Line: SK-Hep-1 cells
Concentration: 2.5 and 5 μM
Incubation Time: 24 hours
Result: Induced cell apoptosis.

分子量

488.54

Formula

C30H24N4O3
CAS 号

1403933-79-8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Chen KF, et al. Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity. Bioorg Med Chem. 2012;20(20):6144-6153.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

PP2A Cancerous-IN-1

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

PP2A Cancerous-IN-1 

PP2A Cancerous-IN-1 是一种强效的 CIP2A (Cancerous inhibitor of PP2A)和 p-Akt 抑制剂。PP2A Cancerous-IN-1显示出很强的抗增殖活性。

PP2A Cancerous-IN-1

PP2A Cancerous-IN-1 Chemical Structure

CAS No. : 1403933-79-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PP2A Cancerous-IN-1 is a strong and potent CIP2A (Cancerous inhibitor of PP2A) and p-Akt inhibitor. PP2A Cancerous-IN-1 shows the most potent antiproliferative activities[1].

IC50 & Target[1]

pAKT

 

体外研究
(In Vitro)

PP2A Cancerous-IN-1 (2.5 and 5 μM; 24 hours; SK-Hep-1 cells) reduces CIP2A expression and cell viability with a dose dependent manner and is more potent in its action than erlotinib[1].
PP2A Cancerous-IN-1 (5 μM; 24 hours; SK-Hep-1 cells) induces cell apoptosis[1].
PP2A Cancerous-IN-1 shows CIP2A inhibitory activity, reduces p-Akt level, induces PARP cleavage. PP2A Cancerous-IN-1 exhibits high potency with low IC50 values of 2.8 μM against HCC cells[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: SK-Hep-1 cells
Concentration: 2.5 and 5 μM
Incubation Time: 24 hours
Result: Reduced cell viability with a dose dependent manner.

Western Blot Analysis[1]

Cell Line: SK-Hep-1 cells
Concentration: 2.5 and 5 μM
Incubation Time: 24 hours
Result: Reduced CIP2A expression.

Apoptosis Analysis[1]

Cell Line: SK-Hep-1 cells
Concentration: 2.5 and 5 μM
Incubation Time: 24 hours
Result: Induced cell apoptosis.

分子量

488.54

Formula

C30H24N4O3
CAS 号

1403933-79-8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Chen KF, et al. Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity. Bioorg Med Chem. 2012;20(20):6144-6153.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务